This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return ...

--Arvinas, Inc. and Pfizer Inc. today announced positive topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen ...

Pfizer Media Contact: +1 (212) 733-1225 PfizerMediaRelations@Pfizer.com Pfizer Investor Contact: +1 (212) 733-4848 IR@Pfizer.com Arvinas Media Contact: ...

NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients ...